Final Program

136 MONDAY • MAY 16
Target Audience
Pulmonologists, post graduate fellows and trainees, advanced practice nurses.
Objectives
At the conclusion of this session, the participant will be able to:
• identify clinical features from a patient’s history that can help distinguish
among the non-IPF ILDs in a patients with newly recognized ILD;
• identify radiographic features from a patient’s HCRT that can help
distinguish among the non-IPF ILDs in a patients with newly recognized
ILD;
• identify pathologic features from a patient’s biopsy that can help distinguish
among the non-IPF ILDs in patients with newly recognized ILD.
Distinguishing among the non-IPF interstitial lung diseases can be very
challenging for the clinician. This symposium will seek to review the evidence
for the best discriminating clinical, pathologic and radiologic features that can be
used to differentiate among the non IPF ILDs. Following a review of these
characteristics, 3 ILD clinicians will discuss real life cases that they will have
been given ahead of time (without the diagnosis) to demonstrate how best to
work thorough these challenging cases.
Chairing: M. Kreider, MD, Philadelphia, PA
G. Tino, MD, Philadelphia, PA
A. Olson, MD, MSPH, Denver, CO
9:00 Introduction
G. Tino, MD, Philadelphia, PA
9:10 Top 5 Clinical Features to Differentiate Among Non-IPF ILD
K.K. Brown, MD, Denver, CO
9:30 Top 5 Radiographic Features to Differentiate Among Non-IPF ILD
D. Hansell, MD, London, United Kingdom
9:45 Top 5 Pathologic Features to Differentiate Among Non-IPF ILD
W.D. Travis, MD, New York, NY
10:00 Case I
T.M. Maher, MD, MSc, PhD, London, United Kingdom
A. Olson, MD, MSPH, Denver, CO
10:15 Case II
C.D. Fell, MD, MSc, Calgary, Canada
M. Kreider, MD, Philadelphia, PA
10:30 Case III
G. Tino, MD, Philadelphia, PA
J.S. Lee, MD, Aurora, CO
10:45 Questions and Answers
M. Kreider, MD, Philadelphia, PA
This session and the International Conference are supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
B4
BASIC • CLINICAL • TRANSLATIONAL
CRITICAL CARE TRACK
CME Credits Available: 2.0
MECHANISMS OF ORGAN FAILURE IN SEPSIS
Assemblies on Critical Care; Respiratory Cell and Molecular Biology;
Respiratory Structure and Function
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3000/3002/3004 (West Building, Level 3)
Target Audience
Pulmonary and critical care researchers (undergraduates, graduates, post
graduates and postdoctoral), clinicians (adults and peds), and trainees interested
in understanding the athophysiology and pathogenesis of organ failure in sepsis.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new paradigms about sepsis-induced organ failure;
• recognize risk and development of sepsis-induced organ failure;
• translate new advancements in basic research with current and future clinical
practice.
This session will review seminal concepts in sepsis-induced organ failure as well
as present novel and cutting edge research in the field. The aim is to translate
cutting-edge advancements in molecular physiology and functional genomics of
organ failure in the septic patient to a broad clinical and translational audience.
The session will engage/stimulate and enhanced understanding of the leading
concepts regarding the relative contributions of over-inflammation,
immunosuppression, the microbiome, epithelium and endothelium as critical
target(s) of organ failure that ultimately determine (lung, kidney, liver, heart,
muscle, gut and brain) dysfunction and clinical outcomes in the critically ill. The
session will have broad appeal to physicians and scientists at any level of training
who work on diverse problems in the critically ill, and it will draw a diverse
international audience because of the generalizability of the topics.
Chairing: C.C. Dos Santos, MD, Toronto, Canada
I.S. Douglas, MD, Denver, CO
J. Chiche, MD, PhD, Paris, France
9:00 Mechanisms of Organ Failure in Sepsis
R. Hotchkiss, MD, St. Louis, MO
9:15 Innate Immune Training in Sepsis?
M. Netea, MD, PhD, Nijmegen, Netherlands
9:30 Liver Dysfunction in Sepsis
M. Bauer, MD, Jena, Germany
9:45 Is the Microbiome an “Organ” that Fails in Septic Patients?
J. Alverdy, MD, Chicago, IL
10:00 Is All Organ Failure Created Equal?
C.C. Dos Santos, MD, Toronto, Canada
10:15 Sepsis Induced Immunosuppression Shift in Therapeutic
Paradigm
J. Chiche, MD, PhD, Paris, France
ATS 2016 • San Francisco